Safety and adherence of early oral immunotherapy for peanut allergy in a primary care setting: a retrospective cross-sectional study
Early oral immunotherapy for peanut allergy in a primary care setting appears to be safe and our findings suggest that it does not lead to an increased burden of emergency department visits. Our population had high adherence rates, with the majority achieving maintenance dose and staying on this dose for one year.
Authors
- Andrew J. Flewelling (ORCID: https://orcid.org/0000-0002-2739-8595)
- Lisa-Qiao MacDonald (ORCID: https://orcid.org/0000-0002-2051-6181)
- Paul Atkinson (ORCID: https://orcid.org/0000-0001-9900-4594)
- C. Vaillancourt
- William M. Lewis (ORCID: https://orcid.org/0000-0002-9465-240X)
- Kavish Chandra (ORCID: https://orcid.org/0000-0001-5758-5810)
- Victoria Landry
- Jacqueline Fraser (ORCID: https://orcid.org/0000-0002-6267-4620)
- Rachel Lewis (ORCID: https://orcid.org/0009-0000-4417-1264)
- Benjamin S. Carson
Institutions
- Dalhousie University (CA)
- Dalsa Corporation (CA)
- Saint John Regional Hospital (CA)
- Horizon Health Network (CA)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1186/s13223-024-00916-5
- Primary Topic
- Food Allergy and Anaphylaxis Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00